Overview

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
Aventis Pharmaceuticals
Treatments:
Carboplatin
Docetaxel